| 41. |
|
|
| 42. |
- Nyström, Helena Filipsson, 1966, et al.
(författare)
-
Incidence Rate and Clinical features of Hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005.
- 2013
-
Ingår i: Clinical endocrinology. - : Wiley. - 1365-2265 .- 0300-0664. ; 78:5, s. 768-776
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVES: To study hyperthyroidism in long-term iodine sufficiency (IS), as iodine supply affects its occurrence. DESIGN: Prospective descriptive study PATIENTS: In 2003-2005, all referred cases of subclinical (SH) and overt hyperthyroidism (OH) were registered at diagnosis from a population (n=631239) in Gothenburg, Sweden. MEASUREMENTS: Information on age, gender, smoking, thyroid associated ophthalmopathy (TAO), thyroid hormones and TSH receptor antibodies (TRab) was collected. Incidences were calculated. SH and OH cases with Graves' disease (GD), toxic multinodular goiter (TMNG) and solitary toxic adenoma (STA) were compared. In GD, TRab+ and TRab- cases and patients with (TAO+) and without TAO (TAO-) were compared. RESULTS: The total incidence (n/100000/year) of hyperthyroidism was 27.6; OH 23.8; SH 3.8; GD 21.4; TMNG 4.3; and STA 1.8. SH was more common among TMNG (40.2%) and STA (45.7%) than in GD (5.9%). SH-GD patients were older, more often smokers and had lower TRab levels than OH-GD patients. FreeT4 and T3 levels in GD were higher than in TMNG and STA. FreeT4, T3 and TRab decreased with age in GD patients, p<0.0001. TRab- patients had lower T3 than TRab+ patients, p<0.001. TRab was positively correlated to FreeT4, p<0.0001. TAO occured in 20% of GD patients. TAO+ patients were younger than TAO- patients. Smokers did not have more TAO. CONCLUSION: The total incidence of hyperthyroidism was low. GD dominated with an age-related decline of thyroid hormones and TRab levels. The spectrum of hyperthyroidism in this long-term IS area may represent the future situation for countries with shorter history of IS. © 2012 Blackwell Publishing Ltd.
|
|
| 43. |
- Nyström, Helena Filipsson, 1966, et al.
(författare)
-
Iodine status in the Nordic countries past and present
- 2016
-
Ingår i: Food & Nutrition Research. - : SNF Swedish Nutrition Foundation. - 1654-6628 .- 1654-661X. ; 60
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Adequate iodine nutrition is dependent on ground water content, seafood, and, as many countries use iodized cow fodder, dairy products. In most countries, salt fortification programs are needed to assure adequate iodine intake. Objectives: The objectives are threefold: 1) to describe the past and present iodine situation in the Nordic countries, 2) to identify important gaps of knowledge, and 3) to highlight differences among the Nordic countries' iodine biomonitoring and fortification policies. Design: Historical data are compared with the current situation. The Nordic countries' strategies to achieve recommended intake and urine iodine levels and their respective success rates are evaluated. Results: In the past, the iodine situation ranged from excellent in Iceland to widespread goiter and cretinism in large areas of Sweden. The situation was less severe in Norway and Finland. According to a 1960 World Health Organization (WHO) report, there were then no observations of iodine deficiency in Denmark. In Sweden and Finland, the fortification of table salt was introduced 5075 years ago, and in Norway and Finland, the fortification of cow fodder starting in the 1950s helped improve the population's iodine status due to the high intake of milk. In Denmark, iodine has been added to household salt and salt in bread for the past 15 years. The Nordic countries differ with regard to regulations and degree of governmental involvement. There are indications that pregnant and lactating women, the two most vulnerable groups, are mildly deficient in iodine in several of the Nordic countries. Conclusion: The Nordic countries employ different strategies to attain adequate iodine nutrition. The situation is not optimal and is in need of re-evaluation. Iodine researchers, Nordic national food administrations, and Nordic governmental institutions would benefit from collaboration to attain a broader approach and guarantee good iodine health for all. © 2016 Helena Filipsson Nyström et al.
|
|
| 44. |
|
|
| 45. |
- Nyström, Helena Filipsson, 1966, et al.
(författare)
-
The metabolic consequences of thyroxine replacement in adult hypopituitary patients.
- 2012
-
Ingår i: Pituitary. - : Springer Science and Business Media LLC. - 1573-7403 .- 1386-341X. ; 15:4, s. 495-504
-
Tidskriftsartikel (refereegranskat)abstract
- The metabolic consequences of thyroxine replacement in patients with central hypothyroidism (CH) need to be evaluated. The aim was to examine the outcome of thyroxine replacement in CH. Adult hypopituitary patients (n=1595) with and without CH from KIMS (Pfizer International Metabolic Database) were studied before and after 2years of GH replacement. CH patients (CH, n=1080) were compared with TSH sufficient patients (TSHsuff n=515) as one group and divided by thyroxine dose/kg/day into tertiles (CHlow-mid-high). Anthropometry, fasting glucose, glycosylated haemoglobin (HbA1c), blood pressure, lipids, IGF-I SDS, quality of life and morbidity were studied. Analyses were standardized for gender, age, number and types of pituitary insufficiencies, stimulated GH peak, age at GH deficiency onset, aetiologies and, when appropriate, for weight and GH dose. At baseline, TSHsuff patients did not differ from CH or CHmid in any outcome. CHlow (≤1.18μg thyroxine/kg/day) had increased weight, BMI and larger waist circumference (WC), CHhigh (≥1.58μg thyroxine/kg/day) had lower weight, BMI, WC and IGF-I than TSHsuff and compared to their predicted weights, BMIs and WCs. For every 0.1μg/kg/day increase of thyroxine dose, body weight decreased 1.0kg, BMI 0.3kg/m(2), and WC 0.65cm. The GH sensitivity of the CH group was higher (0.76±0.56 SDS/mg GH) than that of TSHsuff patients (0.58±0.64 SDS/mg GH), P<0.001. The middle thyroxine dose (1.19-1.57μg/kg/day) seems to be the most physiological. This is equivalent to 70, 100, 125μg thyroxine/day for hypopituitary patients of 50, 70 or 90kg weight, respectively.
|
|
| 46. |
- Onnestam, Lisa, et al.
(författare)
-
National Incidence and Prevalence of TSH-Secreting Pituitary Adenomas in Sweden
- 2013
-
Ingår i: Journal of Clinical Endocrinology and Metabolism. - : Endocrine Society. - 0021-972X .- 1945-7197. ; 98:2, s. 626-635
-
Tidskriftsartikel (refereegranskat)abstract
- Context: TSH-secreting pituitary adenomas (TSHomas) are rare. Epidemiological data are scant and there are no reports on national incidence. less thanbrgreater than less thanbrgreater thanObjective: The objective of the study was to estimate the national Swedish incidence and prevalence of TSHomas. less thanbrgreater than less thanbrgreater thanDesign: This was an observational study. less thanbrgreater than less thanbrgreater thanSetting: The study was conducted at tertiary referral centers. less thanbrgreater than less thanbrgreater thanPatients: The Swedish Pituitary Registry and World Health Organization International Statistical Classification of Diseases and Related Health Problems coding at all university hospitals were used to identify patients diagnosed with TSHomas 1990-2010. The identified patients medical records were studied until the latest follow-up [median 5.0 years (range andlt; 1-20 years)]. less thanbrgreater than less thanbrgreater thanMain Outcome Measurements: Incidence, prevalence, demographics, tumor characteristics, treatment outcome, and thyroid hormone level at diagnosis were measured. less thanbrgreater than less thanbrgreater thanResults: The age-standardized national incidence of 28 TSHoma patients was 0.15 per 1 million inhabitants per year, with an increasing incidence over time (0.05 per 1 million per year in 1990-1994 to 0.26 per 1 million per year in 2005-2009). The national prevalence in 2010 was 2.8 per 1 million inhabitants, in which 0.85 per 1 million had active disease. Most patients (n = 22) underwent pituitary surgery, 5 had radiotherapy, and 6 had somatostatin analogues. Eighteen patients were considered cured at the latest follow-up; 25% remained uncontrolled. Subjects treated for putative primary hyperthyroidism prior to diagnosis had TSH levels more than double those with intact thyroid at diagnosis (P = .013). The median time to diagnosis was longer for women than men (4 vs andlt; 1 year, P = .026). More women than men were treated surgically (94.1% vs 54.5%, P = .022). less thanbrgreater than less thanbrgreater thanConclusion: This is the first estimate of a national incidence of TSHoma. Additional epidemiological studies are needed to compare these results with other geographical areas. This study suggests an increased incidence of TSHomas, in agreement with reports on other pituitary adenomas. (J Clin Endocrinol Metab 98: 626-635, 2013)
|
|
| 47. |
- Ragnarsson, Oskar, 1971, et al.
(författare)
-
Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism.
- 2012
-
Ingår i: Clinical endocrinology. - : Wiley. - 1365-2265 .- 0300-0664. ; 76:2, s. 246-252
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Patients with hypopituitarism have adverse cardiovascular morbidity and reduced bone mineral density (BMD). The objective of this study was to analyze the effects of glucocorticoid (GC) replacement on cardiovascular risk factors and BMD in patients with hypopituitarism. Design, patients and methods: This was a cross-sectional study on 365 patients with hypopituitarism. Two-hundred and four patients (56%) were ACTH insufficient (ACTHins), receiving a mean ± SD hydrocortisone equivalent (HCeq) dose of 20.5 ± 5.8 mg/day. The difference in BMD and cardiovascular risk profile between ACTH sufficient (ACTHsuff) and ACTHins patients, before commencement of GH replacement, was analyzed by multiple linear and logistic regression. Results: ACTHins was independently associated with lower fasting glucose but not other cardiovascular risk factors. The mean HCeq dose per kg body weight was 15% higher in ACTHins women than in ACTHins men (P = 0.009). In women, ACTHins was independently associated with decreased BMD at the lumbar spine (P = 0.002) and femoral neck (P = 0.006) and the presence of osteopenia (P = 0.004). BMD was not different between ACTHins and ACTHsuff men. Conclusion: The current average HCeq dose of approximately 20 mg per day is not associated with an adverse metabolic profile, as compared with ACTHsuff hypopituitary patients. GC replacement in ACTHins women is independently associated with reduced BMD and higher prevalence of osteopenia.
|
|
| 48. |
- Ragnarsson, Oskar, 1971, et al.
(författare)
-
The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients.
- 2014
-
Ingår i: European journal of endocrinology / European Federation of Endocrine Societies. - 1479-683X .- 0804-4643. ; 171:5, s. 571-9
-
Tidskriftsartikel (refereegranskat)abstract
- Quality of life (QoL) is impaired in hypopituitary patients and patients with primary adrenal insufficiency. The aim of this study was to analyse the impact of glucocorticoid (GC) replacement on QoL. The main hypothesis was that ACTH-insufficient patients experience a dose-dependent deterioration in QoL.
|
|
| 49. |
- Robledo-Sierra, J., et al.
(författare)
-
A mechanistic linkage between oral lichen planus and autoimmune thyroid disease
- 2018
-
Ingår i: Oral Diseases. - : John Wiley & Sons. - 1354-523X .- 1601-0825. ; 24:6, s. 1001-1011
-
Tidskriftsartikel (refereegranskat)abstract
- ObjectiveTo determine the levels of antithyroid antibodies and thyroid hormones in the sera of patients with oral lichen planus (OLP), and to quantify the expression of thyroid proteins in OLP lesions. Subjects and MethodsVenous blood samples were drawn from 110 patients with OLP who had no history of thyroid disease or levothyroxine supplementation (OLP+/LT4-). A random population sample of 657 healthy subjects was used as the control group. Two additional groups were used as comparators. Immunohistochemical and qPCR analyses were performed on tissue specimens collected from the patients with OLP and thyroid disease and healthy subjects. ResultsNo association was found between the presence of antithyroid antibodies and OLP. More patients in the OLP+/LT4- group showed high levels of thyroid-stimulating hormone and low levels of free thyroxine than were seen in the control group. Thyroid-stimulating hormone receptor was more highly expressed in the OLP lesions of patients with thyroid disease than in the healthy oral mucosa. ConclusionsA significant number of patients with OLP who are not previously diagnosed with thyroid disease have thyroid parameters that are compatible with hypothyroidism. The expression of thyroid-stimulating hormone receptor in OLP lesions suggests that mechanisms related to autoimmune thyroid disease are involved in the aetiology of OLP.
|
|
| 50. |
- Robledo-Sierra, Jairo, et al.
(författare)
-
Clinical characteristics of patients with concomitant oral lichen planus and thyroid disease.
- 2015
-
Ingår i: Oral surgery, oral medicine, oral pathology and oral radiology. - : Elsevier BV. - 2212-4411 .- 2212-4403. ; 120:5, s. 602-8
-
Tidskriftsartikel (refereegranskat)abstract
- To study the prevalence and profile of thyroid disease in a cohort of referred patients with oral lichen planus (OLP) in comparison with a random population sample and to examine the clinical characteristics of OLP patients with and without thyroid disease.
|
|
